Enveric Biosciences Raises $3.1 Million Through Warrant Exercise to Advance Neuroplastogenic Therapeutics
Key Insights
Enveric Biosciences (search) completed a warrant exercise transaction generating approximately $3.1 million in gross proceeds to fund development of neuroplastogenic small molecules for psychiatric and neurological disorders (search).
The company reduced exercise prices from $36.00 and $10.98 per share to $7.05 per share for 426,390 outstanding warrants, while issuing new Series E and F warrants with five-year and eighteen-month terms respectively.
Proceeds will support development of lead candidate EB-003, designed to selectively engage 5-HT₂A (search) and 5-HT₁B (search) receptors for fast-acting antidepressant and anxiolytic effects without hallucinogenic properties.
Enveric Biosciences (search) (NASDAQ: ENVB) has successfully completed a warrant exercise transaction that generated approximately $3.1 million in gross proceeds to advance its pipeline of neuroplastogenic therapeutics for psychiatric and neurological disorders (search). The Cambridge, Massachusetts-based biotechnology company announced the closing of the exercise of 426,390 outstanding warrants at a significantly reduced price.
Warrant Exercise Details
The company exercised warrants originally issued in February 2025 and September 2025 with exercise prices of $36.00 and $10.98 per share, respectively. These warrants were exercised at a reduced price of $7.05 per share, representing substantial savings for warrant holders. The shares issuable upon exercise are registered under effective registration statements on Form S-1 (No. 333-284277) and Form S-3 (No. 333-290580).
In consideration for the immediate cash exercise, Enveric issued new unregistered Series E and Series F warrants. The Series E warrants allow purchase of up to 426,390 shares at $7.05 per share, are immediately exercisable, and expire five years after the effective date of the Resale Registration Statement. The Series F warrants have identical terms except for an eighteen-month expiration period.
Financial Structure and Use of Proceeds
H.C. Wainwright & Co. (search) acted as the exclusive placement agent for the offering. The gross proceeds include an additional $106,597.50 from warrant holders who paid $0.125 per new unregistered warrant. After deducting placement agent fees and estimated offering expenses, the company intends to use net proceeds for product development, working capital, and general corporate purposes.
Lead Therapeutic Candidate
Enveric's development efforts center on EB-003, described as the first known compound designed to selectively engage both 5-HT₂A (search) and 5-HT₁B (search) receptors. This lead candidate aims to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience while avoiding hallucinogenic effects commonly associated with traditional psychedelic compounds.
The company leverages a differentiated drug discovery platform and maintains a growing library of patent-protected chemical structures to advance novel compounds designed to promote neuroplasticity without hallucinogenic effects.
Regulatory Considerations
The new warrants were offered through private placement under applicable exemptions from Securities Act of 1933 registration requirements. These securities, along with shares issuable upon exercise, have not been registered under the 1933 Act and cannot be offered or sold in the United States without SEC registration or applicable exemptions. Enveric has committed to filing a registration statement with the SEC covering resale of shares issuable upon exercise of the new warrants.